Confident that it will divest all non-core assets by the end of next year, Viatris says it understands “the importance of remaining engaged” with investors during the revamp. Meanwhile, the company is keeping a close eye on foreign exchange rate headwinds moving further into 2022, while electing not to row back further on its 2022 full-year guidance.
Viatris has pledged to keep investors in the loop amid its proposed $9bn global business overhaul, after recognizing “a desire for more clarity and more certainty about our strategic plans and the steps we’re taking to get there.”
In February, the company announced it was offloading its global biosimilars unit to Biocon Biologics